IJARP Impact Factor(2018): 4.908

International Journal of Advanced Research and Publications!

Development And Evaluation Of Gastroretentive Floating Tablet Of Rosuvastatin

Volume 1 - Issue 2, August 2017 Edition
[Download Full Paper]

Author(s)
Amiya kumar Prusty, Archana P. Chand
Keywords
Gastroretentive dosage form, antihyperlipidemic drug, Rosuvastatin, Mucoadhesion.
Abstract
Gastroretentive floating matrix tablets of the antihyperlipidemic drug Rosuvastatin were successfully prepared using hydrophilic polymers like HPMC K4M and Carbapol. From the Preformulation studies for drug excipients compatibility it was observed that there was no compatibility problem with the excipients used in the study. The Formulated tablets gave satisfactory results for various physicochemical evaluation studies like Weight variation, Floating lag time, Content uniformity, Total floating time, Mucoadhesion time, mucoadhesive strength and in vitro drug release and shows a floating time of around 12 hrs.
References
[1]. G Ponchel, J M Irache. “Specific and non-specific bioadhesive particulate system for oral delivery to the gastrointestinal tract”, Advanced Drug Del Review, pp.191-219, 1998.
[2]. A Deshpande, N H Shah, C T Rhodes, W Malick. “evelopment of a novel controlledreleasesystem for gastric retention”, Pharm Research,pp. 815-819,1997.
[3]. S S Davis, A F Stockwell, M J Taylor. “The effect of density on the gastricemptying of single and multiple unit dosage forms”, Pharm Research, pp.208-213,1986.
[4]. J Urguhart, F Theeuwes, “Drug delivery system comprising a reservoircontaining a plurality of tiny pills” US patent 4 434 153. February 28, 1994.
[5]. J A Fix, R Cargill, K Engle. “Controlled gastric emptying. III. Gastric residence time of a non-disintegrating geometric shape in human volunteers”, Pharm Research, pp. 1087-1089,1993.
[6]. R Groning, G Heun. “Oral dosage forms with controlled gastrointestinal transit”, Drug Dev Ind Pharm, pp.527-539 (1984).
[7]. R Groning, G Heun. “Dosage forms with controlled gastrointestinal passage—studies on the absorption of nitrofurantoin”, Int J Pharm, pp.111-116,1989.
[8]. W Wu, Q Zhou, H B Zhang, G D Ma, C D Fu. “Studies on nimodipine sustained release tablet capable of floating on gastric fluids with prolonged gastric resident time”, Yao Xue Xue Bao, pp.86-790, 1997.
[9]. G G Holz and O G Chepurny. “Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus”, Curr. Med. Chem. pp. 2471-2483,2003.
[10]. S Li, S Lin, B.P Daggy, H L Mirchandani, Y W Chien. “Effect of HPMC and Carbopol on the release and floating properties of Gastric Floating Drug Delivery System using factorial design”, Int. J. Pharm, pp.13-22, 2003.
[11]. R N Panigrahy, A M Mahale, D M Sakarkar. “Design development and in vitro testing of a combined bioadhesive-floating oral drug delivery system”, Journal of Pharmacy Research, pp. 212-2215, 2011.
[12]. Y Zhang, M Huo, J Zhou, A Zou, W Li. “DDSolver: An Add-In Program for Modeling and Comparison of Drug Dissolution Profiles”, The AAPS Journal pp. 12, 2010.
[13]. W I Higuchi. “Diffusional models useful in biopharmaceutics-drug release rate processes” J Pharm Sci, pp.315-24, 1967.
[14]. N A Peppas, P L Ritger. “A simple equation for description of solute release II. Fickian and anomalous release from swellable devices” J Control Release, pp.37-42, 1987.